Clinical Study
Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C
| Variables | SVR | P-value | Adjusted OR (95% C.I.) | P-value |
| Sex | | .091 | | .501 | Female | 20/45 (44.4%) | | 1.00 | | Male | 47/77 (61.0%) | | 1.429 (0.506–4.032) | |
| Age (yr) | | .019 | | .398 | 65 | 5/16 (31.3%) | | 1.00 | | 51 64 | 35/68 (51.5%) | | 2.655 (0.581–12.132) | | 50 | 27/38 (71.1%) | | 2.695 (0.574–12.659) | |
| Weight (Kg) | | .028 | | .116 | 65 | 31/68 (45.6%) | | 1.000 | | 65 | 36/54 (66.7%) | | 3.053 (0.760–12.274) | |
| BMI | | .716 | | .158 | 24 | 30/57 (52.6%) | | 1.000 | | 24 | 37/65 (56.9%) | | 2.747 (0.674–11.236) | |
| Viral load (IU/mL) | | .015 | | .174 | 800,000 | 41/86 (47.7%) | | 1.000 | | 100,000 800,000 | 26/36 (72.2%) | | 2.137 (0.716–6.369) | |
| History of IFN treatment | | .203 | | .581 | yes | 26/54 (48.1%) | | 1.000 | | no | 41/68 (60.3%) | | 1.316 (0.496–3.493) | |
| Peg-IFN adherence (%) | | .001 | | .008 | 60 | 6/22 (27.3%) | | 2.637 (0.448–15.513) | .284 | 60 80 | 4/21 (19.0%) | | 1.000 | — | 80 | 57/79 (72.2%) | | 7.702 (1.926–30.798) | .004 |
| RBV adherence (%) | | .001 | | .010 | 60 | 1/19 (5.3%) | | 1.000 | — | 60 80 | 7/17 (41.2%) | | 15.679 (1.289–190.653) | .031 | 80 | 59/86 (68.6%) | | 27.416 (3.130–240.151) | .003 |
|
|